2. Signaling Pathways
  3. Metabolic Enzyme/Protease
  4. Indoleamine 2,3-Dioxygenase (IDO)
  5. Indoleamine 2,3-Dioxygenase (IDO) Degrader

Indoleamine 2,3-Dioxygenase (IDO) Degrader

Indoleamine 2,3-Dioxygenase (IDO) Isoform Comparison

Indoleamine 2,3-Dioxygenase (IDO) Degraders (4):

Cat. No. Product Name Effect Purity
  • HY-173066
    NU227326
    		Degrader
    NU227326 is a blood-brain barrier penetrant IDO1 PROTAC degrader, with a DC50 of 4.5 nM in HiBiT degradation assays. NU227326 degrades IDO1 in U87 and GBM43 cells, with DC50 values of 7.1 nM and 11.8 nM, respectively (WB assays). NU227326 is applicable to research related to glioblastoma, prostate cancer, triple-negative breast cancer, pancreatic cancer, and ovarian cancer.
  • HY-177784
    iDeg-3
    		Degrader
    iDeg-3 is a selective molecular glue degrader that targets IDO1. iDeg-3 can competitively bind to the heme binding site of apo-IDO1, preventing heme binding and inhibiting the enzymatic reaction that converts tryptophan into kynurenine by IDO1 (IC50 = 46 nM). iDeg-3 can be used for the researches of cancer, infection and neurological disease, such as melanoma.
  • HY-177783
    iDeg-1
    		Degrader
    iDeg-1 is a molecular glucose degrading agent that targets the IDO1 protein. iDeg-1 relies on the ubiquitin-proteasome degradation pathway mediated by its natural E3 ligase KLHDC3. iDeg-1 can be used for cancer research.
  • HY-177785
    iDeg-6
    		Degrader
    iDeg-6 is a selective molecular glue degrader that targets IDO1 with a DC50 of 6.5 nM. iDeg-6 can competitively bind to the heme binding site of apo-IDO1, preventing heme binding and inhibiting the enzymatic reaction that converts tryptophan into kynurenine by IDO1 (IC50 = 1.6 μM). iDeg-6 can be used for the researches of cancer, infection and neurological disease, such as melanoma.